RT Journal Article
T1 SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
A1 Piñana, José Luis
A1 López-Corral, Lucia
A1 Martino, Rodrigo
A1 Montoro, Juan
A1 Vazquez, Lourdes
A1 Pérez, Ariadna
A1 Martin-Martin, Gabriel
A1 Facal-Malvar, Ana
A1 Ferrer, Elena
A1 Pascual, María-Jesús
A1 Sanz-Linares, Gabriela
A1 Gago, Beatriz
A1 Sanchez-Salinas, Andrés
A1 Villalon, Lucia
A1 Conesa-Garcia, Venancio
A1 Olave, Maria T
A1 López-Jimenez, Javier
A1 Marcos-Corrales, Sara
A1 García-Blázquez, Marta
A1 Garcia-Gutiérrez, Valentín
A1 Hernández-Rivas, José Ángel
A1 Saus, Ana
A1 Espigado, Ildefonso
A1 Alonso, Carmen
A1 Hernani, Rafael
A1 Solano, Carlos
A1 Ferrer-Lores, Blanca
A1 Guerreiro, Manuel
A1 Ruiz-García, Montserrat
A1 Muñoz-Bellido, Juan Luis
A1 Navarro, David
A1 Cedillo, Angel
A1 Sureda, Anna
A1 Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC), 
AB This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia
YR 2021
FD 2021-11-02
LK http://hdl.handle.net/10668/19952
UL http://hdl.handle.net/10668/19952
LA en
DS RISalud
RD Apr 7, 2025